- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03549689
Effect of Reducing Nucleotide Exposure on Bone Health (ReNew) (ReNew)
Study Overview
Status
Conditions
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- University of Alabama Birmingham
-
-
California
-
Palo Alto, California, United States, 94305
- Stanford University
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado
-
-
Georgia
-
Atlanta, Georgia, United States, 75440
- Emory
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins
-
-
New York
-
New York, New York, United States, 10032
- Columbia
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Penn
-
-
Texas
-
Dallas, Texas, United States, 75216
- Dallas VA Medical Center
-
Houston, Texas, United States, 77030
- UT Houston
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- HIV-1 infection, as documented by a positive 4th generation assay or by any licensed ELISA test kit confirmed by Western blot at any time prior to study entry.
- Age ≥18 years
- HIV-1 RNA BLQ (e.g., <20 copies/mL or other threshold based on the local viral load assay used) for at least 12 months prior to study entry excluding blips (i.e., a single measurement <200 copies/mL preceded and followed by measurements BLQ)
- On a stable TAF-containing ART that also includes at least 2 other antiretrovirals, with no changes in the 12 months prior to entry (except for a switch to a co-formulated tablet from the component tablets or a switch from ritonavir to cobicistat)
- Lumbar spine, femoral neck or total hip BMD T-score ≤-1.0 from a DXA scan within the past 48 weeks
- If receiving testosterone or estrogen replacement therapy, on a stable dose for ≥3 months prior to enrollment without plan to change dose during the study period.
Acceptable blood laboratory values at screening visit:
- CD4+ T-cell count ≥200 cells/µL
- Phosphate ≥2mg/dL
- 25-hydroxyvitamin D level ≥10 ng/ml
Calculated creatinine clearance (CrCl) ≥50 mL/min as estimated by the Cockcroft-Gault equation*:
- For men = CrCl (mL/min) = (140 - age in years) x (body weight in kg) ÷ (serum creatinine in mg/dL x 72)
For women, multiply the above result by 0.85
- For women of reproductive potential, negative serum or urine pregnancy test prior to screening and a negative urine pregnancy test at the entry visit prior to randomization and agreeable to using a contraceptive of choice during the study period.
"Women of reproductive potential" are defined as women who have not been post-menopausal for at least 24 consecutive months (i.e., who have had menses within the preceding 24 months) and have not undergone surgical sterilization (i.e., hysterectomy, bilateral oophorectomy, or tubal ligation; participant report sufficient)
Exclusion Criteria:
- Current systemic glucocorticoid use
- Lumbar spine, femoral neck or total hip BMD T-score <-3.0
- Previous, current pharmacologic treatment, or plan for initiation of therapy for osteoporosis (i.e., bisphosphonates, teriparatide, denosumab, tamoxifen or raloxifene)
- Previous fragility fracture (i.e., any fall from a standing height or less that resulted in a fracture)
- History of genotypic resistance or phenotypic resistance to either DTG or 3TC. The interpretation of genotypic resistance is based on output from the Stanford HIV Resistance Database (available at https://hivdb.stanford.edu). Isolates with an interpretation of low-level resistance or higher are considered resistant.
- History of virologic failure (i.e., confirmed HIV-1 RNA level ≥200 copies/mL after over 6 months of therapy) while on an integrase inhibitor (i.e., raltegravir, elvitegravir, bictegravir, or dolutegravir) or on lamivudine/emtricitabine prior to study enrollment. Any antiretroviral history (even before routine virologic monitoring became standard of care) that would suggest the presence of the M184V mutation should be considered exclusionary
- ALT ≥5 X ULN, OR ALT ≥3xULN and bilirubin ≥1.5xULN (with >35% direct bilirubin)
- Severe hepatic impairment (Child Pugh Class C)
- Anticipated need for antiviral therapy for HCV
- Hepatitis B surface antigen positive or Hepatitis B DNA positive
- Weight >300 pounds, precluding safe DXA testing
- Breastfeeding, pregnancy, or plans to become pregnant during the study
- Known allergy/sensitivity to DTG or 3TC.
- Receipt or planned receipt of prohibited concomitant medications (See section 5.4)
- Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study procedures and treatment.
- Any serious medical or psychiatric illness that, in the opinion of the site investigator, precludes safe participation or adherence to study procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Switch
Dolutegravir (DTG) 50MG/ lamivuidne (3TC) 300MG FIXED_DOSE COMBINATION (FDC) DAILY at randomization for 96 weeks
|
Participants randomized to the Switch Arm will take DTG 50mg/3TC 300mg FDC once daily with or without food at approximately the same time each day.
|
Active Comparator: Continuation
Continue current tenofovir alafenamide (TAF)-containing ART regimen from weeks 0 to 96.
|
Continuation of current TAF-containing ART for 96 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent change in lumbar spine Bone Mineral Density (BMD) at 96 weeks
Time Frame: Baseline and 96 weeks
|
Compare the percentage change from entry to 96 weeks in lumbar spine BMD in those randomized to DTG/3TC vs. those continuing a TAF-based regimen
|
Baseline and 96 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage change in lumbar spine BMD at 48 weeks
Time Frame: Baseline and 48 weeks
|
Compare the percentage change from entry to 48 weeks in lumbar spine BMD in those randomized to DTG/3TC vs. those continuing a TAF-based regimen
|
Baseline and 48 weeks
|
Percentage change in total hip BMD at 48 weeks
Time Frame: Baseline, 48 weeks
|
Compare the percentage change from entry to 48 weeks in total hip BMD in those randomized to DTG/3TC vs. those continuing a TAF-based regimen
|
Baseline, 48 weeks
|
Percentage change in total hip BMD at 96 weeks
Time Frame: Baseline, 96 weeks
|
Compare the percentage change from entry to 96 weeks in total hip BMD in those randomized to DTG/3TC vs. those continuing a TAF-based regimen
|
Baseline, 96 weeks
|
Change in CTX (a bone resorption marker)
Time Frame: Baseline, 12 weeks, 48 weeks, and 96 weeks
|
Compare the changes in CTX from entry to 12, 48, and 96 weeks
|
Baseline, 12 weeks, 48 weeks, and 96 weeks
|
Change in P1NP (a bone deposition marker)
Time Frame: Baseline, 12 weeks, 48 weeks, and 96 weeks
|
Compare the changes in P1NP from entry to 12, 48, and 96 weeks
|
Baseline, 12 weeks, 48 weeks, and 96 weeks
|
Change in urine β2-microglobulin (renal tubular marker)
Time Frame: Baseline, 48 weeks, and 96 weeks
|
Compare the changes in urine β2-microglobulin from entry to 48 weeks and 96 weeks.
|
Baseline, 48 weeks, and 96 weeks
|
Change in urine RBP (renal tubular marker)
Time Frame: Baseline, 48 weeks, and 96 weeks
|
Compare the changes in RBP from entry to 48 weeks and 96 weeks.
|
Baseline, 48 weeks, and 96 weeks
|
Change in urine protein
Time Frame: Baseline, 48 weeks, and 96 weeks
|
Compare the changes in protein from entry to 48 weeks and 96 weeks.
|
Baseline, 48 weeks, and 96 weeks
|
Change in urine albumin
Time Frame: Baseline, 48 weeks, and 96 weeks
|
Compare the changes in urine albumin from entry to 48 weeks and 96 weeks.
|
Baseline, 48 weeks, and 96 weeks
|
Change in fractional excretion in phosphate
Time Frame: Baseline, 48 weeks, and 96 weeks
|
Compare the changes in fractional excretion of phosphate from entry to 48 weeks and 96 weeks.
|
Baseline, 48 weeks, and 96 weeks
|
Percentage change in total lean mass
Time Frame: Baseline, 48 weeks, and 96 weeks
|
Compare the percentage change from entry to 48 weeks and 96 weeks in total lean mass (as measured by whole body DXA)
|
Baseline, 48 weeks, and 96 weeks
|
Percentage change in trunk fat
Time Frame: Baseline, 48 weeks, and 96 weeks
|
Compare the percentage change from entry to 48 weeks and 96 weeks in trunk fat (as measured by whole body DXA)
|
Baseline, 48 weeks, and 96 weeks
|
Percentage change in limb fat
Time Frame: Baseline, 48 weeks, and 96 weeks
|
Compare the percentage change from entry to 48 weeks and 96 weeks in limb fat (as measured by DXA)
|
Baseline, 48 weeks, and 96 weeks
|
Maintenance of HIV RNA level
Time Frame: 48 weeks and 96 weeks
|
Compare the levels of HIV RNA <50 copies/mL and below the limit of quantification (BLQ) at 48 weeks and 96 weeks using the FDA snapshot algorithm
|
48 weeks and 96 weeks
|
Grade 3 or 4 adverse events
Time Frame: 96 weeks
|
Compare rates of grade 3 or 4 adverse events experienced by participants through 96 weeks
|
96 weeks
|
Treatment discontinuation of study medication due to adverse effect
Time Frame: 96 weeks
|
Compare treatment discontinuation of study medication due to adverse effect experienced by participants through 96 weeks
|
96 weeks
|
Change in fasting lipids
Time Frame: Entry, 48 weeks, and 96 weeks
|
Compare changes in fasting lipids (total cholesterol, LDL, HDL, and triglycerides) at entry, 48 weeks, and 96 weeks
|
Entry, 48 weeks, and 96 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Philip Grant, MD, Stanford University
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Musculoskeletal Diseases
- Bone Diseases
- Bone Diseases, Metabolic
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- HIV Integrase Inhibitors
- Integrase Inhibitors
- Tenofovir
- Lamivudine
- Dolutegravir
Other Study ID Numbers
- 43453
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV/AIDS
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
University of Massachusetts, BostonCompleted
-
Stanford UniversityJanssen Services, LLCCompleted
-
ViiV HealthcareJohns Hopkins University; Pfizer; Vanderbilt University; University of North Carolina...Completed
-
Medical College of WisconsinCompleted
-
Emory UniversityCompleted
-
Rhode Island HospitalUnknown
-
Tibotec Pharmaceuticals, IrelandCompleted
-
Lampiris, Harry W., M.D.AbbottUnknown
Clinical Trials on Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC)
-
Centre for the AIDS Programme of Research in South...Johns Hopkins University; National Institute of Allergy and Infectious Diseases... and other collaboratorsActive, not recruitingHIV/AIDS | Tuberculosis, PulmonarySouth Africa
-
ViiV HealthcareCompletedInfection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareGlaxoSmithKlineCompletedHIV Infections | Infection, Human Immunodeficiency VirusUnited States, Argentina, Spain, Germany, Belgium, Australia, Canada, United Kingdom, Italy, Romania, Taiwan, Russian Federation, Mexico, France, Switzerland, Peru, Poland, Portugal
-
ViiV HealthcareGlaxoSmithKline; PPDCompletedHIV Infections | Infection, Human Immunodeficiency VirusTaiwan, France, Germany, Belgium, United States, Canada, Netherlands, Spain, Korea, Republic of, Italy, Australia, United Kingdom, Russian Federation, Portugal, Argentina, South Africa, Romania, Mexico
-
Rhonda BrandNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV | Medication AdherenceUnited States
-
GlaxoSmithKlineCompleted
-
ANRS, Emerging Infectious DiseasesNot yet recruiting